BioCryst Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
JMP Securities Downgrades BioCryst Pharma (BCRX) to Market Perform
August 4, 2016 9:58 AM EDTJMP Securities downgraded BioCryst Pharma (NASDAQ: BCRX) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $4.03 yesterday.
... MoreBioCryst Pharma (BCRX) Tops Q2 EPS by 4c
August 4, 2016 8:35 AM EDTBioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.8 million versus the consensus estimate of $3.92 million.
Cash, cash equivalents and investments decreased to $64.3 million at June 30, 2016, as compared to $100.9 million at... More
